InMed Pharmaceuticals Inc.
NASDAQ Global SelectTotal Valuation
InMed Pharmaceuticals Inc. carries a market capitalization of 2.88M, placing it among publicly traded companies globally. Its enterprise value stands at -1.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.88M |
| Enterprise Value | -1.16M |
Share Statistics
InMed Pharmaceuticals Inc. currently has 3.31M shares outstanding.
| Shares Outstanding | 3.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.10, and the price-to-book ratio stands at -0.11.
| PE Ratio | N/A |
| PS Ratio | 1.10 |
| PB Ratio | -0.11 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | -0.48 |
| P/OCF Ratio | -0.48 |
Enterprise Valuation
| EV / Sales | 0.95 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
InMed Pharmaceuticals Inc. maintains a current ratio of 3.11, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.10, indicating elevated leverage, while an interest coverage ratio of -398.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.11 |
| Quick Ratio | 2.33 |
| Debt / Equity | 6.10 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -398.18 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -92.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.11 |
Stock Price Statistics
InMed Pharmaceuticals Inc.'s stock has declined approximately -46.6443% over the past 52 weeks. The 50-day moving average sits at 0.88, while the 200-day moving average is 1.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.6443% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.37 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, InMed Pharmaceuticals Inc. generated 3.25M in revenue and converted that into -8.51M in net income, yielding earnings per share of -2.09. EBITDA reached -7.96M, while operating income came in at -8.54M.
| Revenue | 3.25M |
| Gross Profit | 1.16M |
| Operating Income | -8.54M |
| Pretax Income | -8.34M |
| Net Income | -8.51M |
| EBITDA | -7.96M |
| EBIT | -8.54M |
| Earnings Per Share (EPS) | -2.09 |
Balance Sheet
InMed Pharmaceuticals Inc. holds 5.16M in cash and equivalents against 420,147.00 in total debt, resulting in a net debt position of -5.16M. Total book value stands at -31.38M, with working capital of 4.68M providing operational flexibility.
| Cash & Cash Equivalents | 5.16M |
| Total Debt | 420,147.00 |
| Net Debt | -5.16M |
| Equity (Book Value) | -31.38M |
| Book Value Per Share | -7.87 |
| Working Capital | 4.68M |
Cash Flow
InMed Pharmaceuticals Inc. produced -7.46M in operating cash flow over the past twelve months.
| Operating Cash Flow | -7.46M |
| Capital Expenditures | N/A |
| Free Cash Flow | -7.46M |
| FCF Per Share | -1.87 |
Margins
InMed Pharmaceuticals Inc. operates with a gross margin of 35.87, reflecting its pricing power and cost economics. The operating margin of -263.26 and net profit margin of -262.24 provide insight into operational efficiency.
| Gross Margin | 35.87 |
| Operating Margin | -263.26 |
| Pretax Margin | -256.86 |
| Profit Margin | -262.24 |
| EBITDA Margin | -245.41 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -231.28 |
| FCF Yield | -208.58 |
Stock Splits
InMed Pharmaceuticals Inc.'s most recent stock split took place on November 14, 2024 with a 20:1 split ratio.
| Last Split Date | 11/14/2024 |
| Split Ratio | 20:1 |
Scores
InMed Pharmaceuticals Inc. posts an Altman Z-Score of -24.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.30 |